ClinicalTrials.gg
TerminatedNCT06627166VERIFYUpdated Oct 4, 2024

Viral Etiology of Severe Acute Respiratory InFection in CriticallY Ill Patients Registry

An observational study in Severe Acute Respiratory Infection, sponsored by King Abdullah International Medical Research Center. Terminated at 1 site in Saudi Arabia. Open to participants aged 14 Years and older. Per ClinicalTrials.gov, last updated 2024-10-04.

Primary conditionInfectionsRegistry: Critical IllnessReclassifiedWhy we changed it
Registry
Critical Illness — the first condition term the registry derived for this study.
ClinicalTrials.gg
Infections
Why
  1. Critical Illness is a broad heading, used only when no more specific condition is named.
  2. The study's listed conditions name Infections.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by King Abdullah International Medical Research Center · Observational

How we know

Why this study was terminated
Due to recruitment failure

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
13
Ages
14 Years and older
Sex
All
01

Study summary

SARI is a major public health problem in Saudi Arabia and leads to considerable morbidity and mortality. Most SARI-related mortality occurs in patients admitted to ICUs across the country. RVIs alone and as precipitating causes of bacterial co-infections are under-recognized as causes of critical SARI. Therefore, data regarding the role of RVIs in critically ill patients with SARI in Saudi Arabia are greatly needed to fill the current gaps with respect to pathogens, disease pathogenesis, current treatment approaches, and clinical outcomes.

In the VERIFY multicenter national registry, we aim to determine the viral etiologies of SARI in mechanically ventilated critically ill patients. We aim to collect inventory samples (blood, and nasopharyngeal swabs, mini BAL) from >10 sites in Saudi Arabia from different regions to enhance generalizability of data.

Read the detailed description

Data on the burden, severity and etiology of SARI amongst critically ill patients will be expected to be of a great value in guiding the prioritization of prevention and control efforts18 and in the design of future intervention studies of antivirals and other therapeutic modalities.

Because influenza is a common cause of serious respiratory illness in Saudi Arabia, although only limited data are available on the most severely ill patients with influenza, we will conduct surveillance in SARI critically ill patients and perform typing and subtyping of influenza viruses in BAL samples. We will store samples for future examination of predisposing risk factors including genetic factors.

Multiplex PCR will reduce the cost and time to detect the respiratory pathogens. In recent years, the falling costs of Whole Genome Sequencing (WGS) technologies have has proven to be a valuable tool to understand the growing threat of emerging pathogens. Metagenomic next-generation sequencing (M-NGS) has transformative effect in the last decade to investigate and understand complex microbial communities. M-NGS is simply capturing and determining all nucleic acids in a sample which allowed to identify a mixed population of microorganisms. This powerful platform simultaneously identifies genetics materials of any organisms unbiased to other methods that used specific primers to identify specific targets.

The primary objective of the VERIFY registry is to examine the virological etiologies of SARI among mechanically ventilated critically ill patients in a geographical representative sample from Saudi Arabia in order to obtain a better estimate of viral pathogen prevalence by systematic lower respiratory tract sampling and use of serology among critically ill patients in a geographical representative sample from Saudi Arabia. Contribution of viruses may be under-estimated due to the use of upper respiratory tract specimens only, and late presentation of cases to ICU (at which time antigen is no longer detectable). Therefore a systematic approach using mini-BAL to obtain lower respiratory samples will likely yield better estimate.

02

Conditions studied

  • Severe Acute Respiratory Infection

Browse trials for

Keywords

  • SARI
  • Critically ill
  • Infection
  • viruses
03

In context

Infections Reclassified

2,097 studies on the registry are indexed under Infections; 361 are open to participants now.

This study's enrollment of 13 is below the median of 300 across 688 observational studies indexed under Infections.

Browse Infections studies →

Lead sponsor

King Abdullah International Medical Research Center is the lead sponsor of 46 studies on the registry; 6 are open to participants now.

Compared within Infections, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Critical Illness. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
14 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

All eligible patients with SARI in critical care setting.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults (≥14 years old) patients
  • A clinical presentation consistent with community-acquired SARI/pneumonia
  • AND admitted to the ICU because of respiratory failure or sepsis
  • AND is invasively mechanically ventilated.

Exclusion criteria

Exclusion Criteria:

  • Diagnosed with COVID-19
  • Duration of illness > 14 days since symptom onset
  • Did not meet inclusion criteria in the first 48 hrs of admission to the ICU.
  • Patient already enrolled in the study
  • Participant or legal guardian refuses to participate in the study.
  • Diagnosis is not related to SARI
  • Enrolled in interventional trial of therapeutics for pneumonia.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
13 participants (actual)
Target follow-up
90 Days
Patient registry
Yes
Biospecimen retention
Samples without dna

Groups and cohorts

  • Severe Acute Respiratory Infection (SARI)

    Nasopharyngeal swab, MINI BAL samples, Serum samples, Plasma sample, and Blood sample (RNA) will be collected from patients on day 0 (baseline) of enrollment, and on day 14 of enrollment. SAMPLING PROCEDURES: 1. Nucleic acid extraction 2. Polymerase chain reaction (PCR) 2.1 Testing for MERS-CoV will be performed by RT-PCR 2.2 We will test for Infleunza H and N PCR for influenza H 2.3 We will also test for a panel of viruses using PCR multiplex that includes influenza A ; influenza B ; influenza C ; influenza A (H1N1) swl ; parainfluenza viruses 1, 2, 3 and 4 ; coronaviruses NL63, 229E, OC43 and HKU1; human metapneumoviruses A/B; rhinovirus ;respiratory syncytial viruses A and B; adenovirus; enterovirus; parechovirus; bocavirus. 3.16S PCR and sanger sequencing for bacterial detection 4.Metagenomics /Next Generation Sequencing 5.Microbiome bioinformatics analysis

06

What researchers measure

Primary outcomes

  1. Prevalence of different viral and bacterial pathogens among critically ill patients with SARI

    Viral pathogens include influenza virus and MERS corona virus

    Time frame: 14 Days

Secondary outcomes

  1. Clinical features and response to treatment of SARI of different etiologies.

    Clinical data collection include demographic (Age in years, BMI in kg/m\^2)

    Time frame: 90 days

  2. Clinical features and response to treatment of SARI of different etiologies.

    Risk factors (Admission diagnosis, smoking, chronic comorbidities)

    Time frame: 90 days

  3. Clinical features and response to treatment of SARI of different etiologies.

    Clinical course in the ICU (mechanical ventilation, vasopressor use, renal replacement therapy, tracheostomy)

    Time frame: 90 days

  4. Clinical features and response to treatment of SARI of different etiologies.

    outcomes (90 day mortality, ICU length of stay, hospital length of stay, mechanical ventilation duration)

    Time frame: 90 days

07

Study locations

1 site
  • Intensive Care Department, King Abdulaziz Medical City, National Guard Health Affairs
    Riyadh, 11426, Saudi Arabia
08

References and documents

Publications

  • Huai Y, Guan X, Liu S, Uyeki TM, Jiang H, Klena J, Huang J, Chen M, Peng Y, Yang H, Luo J, Zheng J, Peng Z, Huo X, Xiao L, Chen H, Zhang Y, Xing X, Feng L, Hu DJ, Yu H, Zhan F, Varma JK. Clinical characteristics and factors associated with severe acute respiratory infection and influenza among children in Jingzhou, China. Influenza Other Respir Viruses. 2017 Mar;11(2):148-156. doi: 10.1111/irv.12419. Epub 2016 Sep 20. PubMed 27465959 ↗
  • Nguyen HKL, Nguyen SV, Nguyen AP, Hoang PMV, Le TT, Nguyen TC, Hoang HT, Vuong CD, Tran LTT, Le MQ. Surveillance of Severe Acute Respiratory Infection (SARI) for Hospitalized Patients in Northern Vietnam, 2011-2014. Jpn J Infect Dis. 2017 Sep 25;70(5):522-527. doi: 10.7883/yoken.JJID.2016.463. Epub 2017 Mar 28. PubMed 28367882 ↗
  • Meerhoff TJ, Simaku A, Ulqinaku D, Torosyan L, Gribkova N, Shimanovich V, Chakhunashvili G, Karseladze I, Yesmagambetova A, Kuatbayeva A, Nurmatov Z, Otorbaeva D, Lupulescu E, Popovici O, Smorodintseva E, Sominina A, Holubka O, Onyshchenko O, Brown CS, Gross D. Surveillance for severe acute respiratory infections (SARI) in hospitals in the WHO European region - an exploratory analysis of risk factors for a severe outcome in influenza-positive SARI cases. BMC Infect Dis. 2015 Jan 8;15:1. doi: 10.1186/s12879-014-0722-x. PubMed 25567701 ↗
  • Ruuskanen O, Lahti E, Jennings LC, Murdoch DR. Viral pneumonia. Lancet. 2011 Apr 9;377(9773):1264-75. doi: 10.1016/S0140-6736(10)61459-6. Epub 2011 Mar 22. PubMed 21435708 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2022 to primary completion in Apr 2022, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2023
First posted
Oct 4, 2024
StartActual
Mar 20, 2022
Primary completionActual
Apr 18, 2022
CompletionActual
Jun 22, 2022
Last update
Oct 4, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 4, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06627166
Lead sponsor
King Abdullah International Medical Research Center
Responsible party
Dr Yaseen Arabi (Chairman intensive care unit, King Abdullah International Medical Research Center) — Principal investigator
First posted
Oct 4, 2024
Start date
Mar 20, 2022
Primary completion
Apr 18, 2022
Completion
Jun 22, 2022
Last update
Oct 4, 2024

Study contacts

Yaseen Arabi
principal investigator · King Abdulaziz Medical City

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion